FIELD: immunology.
SUBSTANCE: disclosed is a method of selecting an allogenic T-cell line, comprising selecting a T-cell line using representation, which identifies a plurality of HLA alleles and describes signs of relative activities of T-cell lines, each of which recognizes an epitope of a malignant tumor antigen and is limited by different versions of HLA alleles or combinations of HLA alleles, wherein in representation, each identified HLA allele or a combination of HLA alleles are associated with a corresponding feature of the relative activity of a T-cell line limited by a HLA allele or a combination of HLA alleles.
EFFECT: present method can be used in adoptive cancer therapy.
22 cl, 1 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE USING ALLOGENIC T-CELLS | 2017 |
|
RU2773831C2 |
| METHODS OF MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA TREATMENT BY T-CELL THERAPY | 2016 |
|
RU2743381C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| LINE OF CELLS OF HUMAN MELANOMA KG, SECRETING RECOMBINANT GRANULOCYTIC MACROFAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2362805C1 |
| IMMUNOLOGICALLY DISTINCT CELL SURFACE VARIANTS FOR CELL THERAPY APPLICATIONS | 2017 |
|
RU2793803C2 |
| HUMAN MELANOMA CELL LINE 31G WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395573C1 |
| HUMAN MELANOMA CELL LINE 26G WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395571C1 |
| HUMAN MELANOMA CELL LINE IG WHICH SECRETES RECOMBINANT GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR | 2008 |
|
RU2395572C1 |
| METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CD4+ T-CELL CHARACTERIZATION | 2019 |
|
RU2826261C2 |
